Edesa Biotech Inc.

We are a clinical-stage biopharmaceutical company exploring new ways to treat inflammatory and immune-related diseases

[Edesa Biotech Inc. @EdesaBiotech]

Exploratory data on #paridiprubart in patients with acute kidney injury (#AKI) and respiratory distress to be presented today at #ERA26. https://t.co/CWT1LzoJgY

[Edesa Biotech Inc. @EdesaBiotech]

Edesa plans to present new #paridiprubart data in patients with acute #kidney injury and respiratory distress at the annual #ERA26 Congress, to be held June 3-6, 2026 in Scotland #AKI #ARDS $EDSA https://t.co/M0UyJzS798.

[Edesa Biotech Inc. @EdesaBiotech]

Edesa Biotech today reported #financialresults for fiscal 2Q 2026 $EDSA #vitiligo #ARDS https://t.co/krlQGrdUET

[Edesa Biotech Inc. @EdesaBiotech]

Edesa is pleased to announce that our CEO, Dr. Par Nijhawan, has been selected to deliver the inaugural presentation at the #RIS2026 Oral Showcase at #ATS2026 #ARDS $EDSA https://t.co/4ZJoJ72o5j

[Edesa Biotech Inc. @EdesaBiotech]

Edesa Biotech advances #vitiligo clinical development program, selects JSS Medical Research as CRO for planned Phase 2 study. https://t.co/wrROX1IfOk $EDSA #dermatology #AAD2026

[Edesa Biotech Inc. @EdesaBiotech]

Additional clinical data from Edesa’s #Phase3 study affirmed statistically significant mortality reductions in the full population of 278 patients. Exploratory analysis also demonstrated reduced mortality in #AKI, #sepsis and #pneumonia. https://t.co/hLsR4t58q6

[Edesa Biotech Inc. @EdesaBiotech]

Edesa Biotech today reported #financialresults for fiscal 1Q 2026 $EDSA #vitiligo #ARDS https://t.co/yzdtS1rAPa

[Edesa Biotech Inc. @EdesaBiotech]

Edesa Biotech today reported #financialresults for fiscal year 2025 $EDSA https://t.co/bsQbwL4G71

[Edesa Biotech Inc. @EdesaBiotech]

Edesa’s #Phase3 study of paridiprubart in patients with #ARDS met its primary and secondary endpoints, showing demonstrating a statistically significant and clinically meaningful benefit for reduced mortality at 28 days. $EDSA #biotech #drugdevelopment
https://t.co/02XG2JFhZY

[Edesa Biotech Inc. @EdesaBiotech]

Edesa to participate in the @HCWCO 27th Annual Global Investment Conference next week in New York #HCWConference #vitiligo #ARDS $EDSA

[Edesa Biotech Inc. @EdesaBiotech]

Edesa Biotech today reported #financialresults for fiscal 3Q 2025 $EDSA https://t.co/vj40QITj61

[Edesa Biotech Inc. @EdesaBiotech]

Edesa Biotech is a proud sponsor and supporter of World #Vitiligo Day and this year’s theme “Innovation for Every Skin” #WVD2025 #biotechnology #CXCL10 $EDSA https://t.co/UM0SbgaJnJ

[Edesa Biotech Inc. @EdesaBiotech]

Edesa Biotech today reported #financialresults for fiscal 2Q 2025 $EDSA https://t.co/2R1QWH7nTs

[Edesa Biotech Inc. @EdesaBiotech]

Edesa to join the annual Bloom Burton Healthcare Investor #Conference next week. $EDSA #vitiligo #BBHIC2025 https://t.co/7Xwjrdgp3C

[Edesa Biotech Inc. @EdesaBiotech]

Edesa is pleased to announce that Peter Weiler will assume the role of CFO on May 1. Peter is a veteran of the #pharma and #biotech sectors, with extensive experience in finance and corporate strategy. https://t.co/uJ5mHY9iF8

[Edesa Biotech Inc. @EdesaBiotech]

Congratulations to the Global #Vitiligo Foundation for hosting a great scientific symposium this week at #AAD2025. Edesa is proud to provide support for advancing research, education and collaboration within the vitiligo community.

[Edesa Biotech Inc. @EdesaBiotech]

Edesa Biotech today reported #financialresultsfor fiscal 1Q 2025 #vitiligo #ACD #ARDS #fibrosis $EDSA https://t.co/4tm7q6xGVe

[Edesa Biotech Inc. @EdesaBiotech]

Edesa Biotech Announces $15m private placement led by Velan Capital with participation from new and existing healthcare-focused institutional investors and insiders. https://t.co/sfcAK1mfjB

[Edesa Biotech Inc. @EdesaBiotech]

Edesa Biotech today reported #financialresults for FY 2024 #vitiligo #ACD #ARDS #fibrosis $EDSA https://t.co/PqUmKVPiDJ

[Edesa Biotech Inc. @EdesaBiotech]

$EDSA announced today that the company’s CEO & Founder, Dr. Par Nijhawan, will invest up to $5 million in Edesa, including an immediate investment of ~$1.5 million. >> https://t.co/HEO4TAtqnQ #vitiligo #ACD #ARDS #fibrosis #biotech